Abstract：
OBJECTIVE: To determine the effect of polymorphisms and mutations in angiotensin-converting enzyme 2 (ACE2) and Type 2 transmembrane serine proteases (TMPRSS2) genes on susceptibility to corona virus disease 2019 (COVID-19) and patient prognosis.
BACKGROUND: From December 2019 to the current time, an outbreak of epidemic of COVID-19, characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred around the world. It is now clear that SARS-CoV-2 binds to human ACE2 receptors, with expression of these receptors correlated with the rate of SARS-CoV-2 infection and mortality. Polymorphisms in individual patient factors, such as ACE2 and TMPRSS2 genes have been linked with an increase in negative outcomes, although evidence to affirm remains debatable.
METHODS: Here, we performed a systematic review, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, with the aim of assessing whether polymorphisms in ACE2 and TMPRSS2 genes affect the COVID-19 condition. We extensively searched PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science databases, for relevant articles and reports published in English between December 2019 and December 2021.
RESULTS: A total of 495 full-text articles were downloaded, of which 185 were excluded after preliminary examination as they were duplicates. Finally, 310 articles were evaluated, by reading their titles and abstracts, and 208 of them eliminated based on our selection criteria. Finally, 33 articles met our inclusion criteria and were included in the final assessment. Genetic data from 33,923 patients with COVID-19 drawn from the general population and deriving from over 160 regions and 50 countries, as well as approximately 560,000 samples from global-public genetic databases, were included in our analysis. Ultimately, we identified 10 SNPs and 21 mutations in the ACE2 gene, along with 13 SNPs and 12 variants in the TMPRSS2 gene, which may be associated with COVID-19.
CONCLUSIONS: ACE2 and TMPRSS2 play vital roles in the onset, development, and prognosis of SARS-CoV-2 infection, and have both been strongly associated with vulnerability, intensity, and the clinical result of COVID-19. Overall, these genetic factors may have potential for future development of personalized drugs and vaccines against COVID-19.
BACKGROUND: CRD42021239400 in PROSPERO 2021.
BACKGROUND: From December 2019 to the current time, an outbreak of epidemic of COVID-19, characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occurred around the world. It is now clear that SARS-CoV-2 binds to human ACE2 receptors, with expression of these receptors correlated with the rate of SARS-CoV-2 infection and mortality. Polymorphisms in individual patient factors, such as ACE2 and TMPRSS2 genes have been linked with an increase in negative outcomes, although evidence to affirm remains debatable.
METHODS: Here, we performed a systematic review, based on guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria, with the aim of assessing whether polymorphisms in ACE2 and TMPRSS2 genes affect the COVID-19 condition. We extensively searched PubMed, MEDLINE, Embase, the Cochrane Library, and Web of Science databases, for relevant articles and reports published in English between December 2019 and December 2021.
RESULTS: A total of 495 full-text articles were downloaded, of which 185 were excluded after preliminary examination as they were duplicates. Finally, 310 articles were evaluated, by reading their titles and abstracts, and 208 of them eliminated based on our selection criteria. Finally, 33 articles met our inclusion criteria and were included in the final assessment. Genetic data from 33,923 patients with COVID-19 drawn from the general population and deriving from over 160 regions and 50 countries, as well as approximately 560,000 samples from global-public genetic databases, were included in our analysis. Ultimately, we identified 10 SNPs and 21 mutations in the ACE2 gene, along with 13 SNPs and 12 variants in the TMPRSS2 gene, which may be associated with COVID-19.
CONCLUSIONS: ACE2 and TMPRSS2 play vital roles in the onset, development, and prognosis of SARS-CoV-2 infection, and have both been strongly associated with vulnerability, intensity, and the clinical result of COVID-19. Overall, these genetic factors may have potential for future development of personalized drugs and vaccines against COVID-19.
BACKGROUND: CRD42021239400 in PROSPERO 2021.
摘要：
目的：确定血管紧张素转换酶2（ACE2）和2型跨膜丝氨酸蛋白酶（TMPRSS2）基因多态性和突变对2019年冠状病毒病（COVID-19）易感性和患者预后的影响。
背景：从2019年12月到当前时间，以严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）为特征的COVID-19疫情在世界各地爆发。现在很清楚SARS-CoV-2与人ACE2受体结合，这些受体的表达与SARS-CoV-2感染率和死亡率相关。个体患者因素中的多态性，如ACE2和TMPRSS2基因与负面结果的增加有关，尽管确认的证据仍有争议。
方法：这里，我们进行了系统的回顾,根据系统审查和荟萃分析(PRISMA)标准的首选报告项目指南，目的是评估ACE2和TMPRSS2基因的多态性是否影响COVID-19病情。我们广泛搜索了PubMed,MEDLINE,Embase,Cochrane图书馆,和WebofScience数据库,获取2019年12月至2021年12月以英文发布的相关文章和报告。
结果：共下载了495篇全文，其中185个在初步检查后被排除，因为它们是重复的。最后,对310篇文章进行了评估，通过阅读他们的标题和摘要，根据我们的选择标准，其中208人被淘汰。最后,33篇文章符合我们的纳入标准，并被纳入最终评估。来自普通人群的33,923例COVID-19患者的遗传数据来自160多个地区和50个国家，以及来自全球公共遗传数据库的大约560,000个样本，包括在我们的分析中。最终,我们在ACE2基因中鉴定出10个SNPs和21个突变,连同TMPRSS2基因中的13个SNP和12个变异，可能与COVID-19有关。
结论：ACE2和TMPRSS2在发病中起着至关重要的作用，发展,SARS-CoV-2感染的预后，两者都与脆弱性密切相关，强度,和COVID-19的临床结果。总的来说,这些遗传因素可能对未来开发针对COVID-19的个性化药物和疫苗具有潜力.
背景：PROSPERO2021中的CRD42021239400。
背景：从2019年12月到当前时间，以严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）为特征的COVID-19疫情在世界各地爆发。现在很清楚SARS-CoV-2与人ACE2受体结合，这些受体的表达与SARS-CoV-2感染率和死亡率相关。个体患者因素中的多态性，如ACE2和TMPRSS2基因与负面结果的增加有关，尽管确认的证据仍有争议。
方法：这里，我们进行了系统的回顾,根据系统审查和荟萃分析(PRISMA)标准的首选报告项目指南，目的是评估ACE2和TMPRSS2基因的多态性是否影响COVID-19病情。我们广泛搜索了PubMed,MEDLINE,Embase,Cochrane图书馆,和WebofScience数据库,获取2019年12月至2021年12月以英文发布的相关文章和报告。
结果：共下载了495篇全文，其中185个在初步检查后被排除，因为它们是重复的。最后,对310篇文章进行了评估，通过阅读他们的标题和摘要，根据我们的选择标准，其中208人被淘汰。最后,33篇文章符合我们的纳入标准，并被纳入最终评估。来自普通人群的33,923例COVID-19患者的遗传数据来自160多个地区和50个国家，以及来自全球公共遗传数据库的大约560,000个样本，包括在我们的分析中。最终,我们在ACE2基因中鉴定出10个SNPs和21个突变,连同TMPRSS2基因中的13个SNP和12个变异，可能与COVID-19有关。
结论：ACE2和TMPRSS2在发病中起着至关重要的作用，发展,SARS-CoV-2感染的预后，两者都与脆弱性密切相关，强度,和COVID-19的临床结果。总的来说,这些遗传因素可能对未来开发针对COVID-19的个性化药物和疫苗具有潜力.
背景：PROSPERO2021中的CRD42021239400。
